Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irbesartan in heart failure with preserved systolic function (I-PRESERVE)

Trial Profile

Irbesartan in heart failure with preserved systolic function (I-PRESERVE)

Phase of Trial: Phase III

Latest Information Update: 04 Jan 2017

At a glance

  • Drugs Irbesartan (Primary)
  • Indications Heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms I-PRESERVE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 04 Jan 2017 Results of subgroup analysis from patients with or without diabetes published in the Circulation.
    • 15 May 2016 Primary endpoint (Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given Timepoints) has been met according to the results published in the European Journal of Heart Failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top